Home >  News >  August, 2014

Drug Mix-Up Blinds Patient, Spurs Malpractice Verdict

Cataract patient given methylene blue instead of VisionBlue.

Published: August 22, 2014

A mix-up over sound-alike drugs is at the heart of a $1.5 million jury award earlier this week stemming from a botched cataract procedure that left a patient blind in one eye.

You might say the cataract team at North Carolina Specialty Hospital blue it. Ophthalmologist Timothy Young, MD, PhD, who at the time was practicing with co-defendant North Carolina Eye, Ear, Nose and Throat, in Durham, called for the ophthalmic dye VisionBlue during a cataract removal in 2008, according to news reports. But a nurse instead retrieved methylene blue, a compound sometimes used in endoscopic polypectomies and one that's toxic to eyes.

Both the nurse and a surgical technician testified that they announced what the drug was before it was given to Dr. Young, but he testified that he didn't hear them.

A second procedure to repair the severe damage caused by the mix-up failed, as did a full corneal transplant.

Calls for comment by Outpatient Surgery Magazine to Dr. Young, who now practices in Texas, and to North Carolina Eye, Ear, Nose and Throat, were not returned.

Jim Burger


Also in the News...

Morcellator Opponent Amy Reed, MD, Succumbs to Cancer
Judge Awards $88K to Surgeon "Forced Out" for Double-Booking Complaints
Doctor, 2 Nurses Jailed Without Bail After Child Sex Videos Emerge
Inspiration of Informed Consent Dead at 78
Watch: Surgeon and Nurse Duke it Out Inside a Hospital in China
Male Nurse Charged With Sexual Assault at Atlanta Endo Center
Gastric Bypass May Put Patients at Risk of Alcohol Problems

New to Outpatient Surgery Magazine?
Sign-up to continue reading this article.
Register Now
Have an account? Please log in:
Email Address:
  Remember my login on this computer

advertiser banner

Other Articles That May Interest You

News & Notes

News & Notes

Study: Stair-Climbing Speed Accurately Predicts Surgical Complications

Researchers say it outperformed the ACS risk calculator.